Dr. Reddy’s Laboratories Launch Sevelamer Carbonate for Oral Suspension in U.S. Market
Posted on January 2, 2019
Dr. Reddy’s Laboratories Ltd. (, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).
The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October 2018 according to IMS Health*.
Dr. Reddy’s Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90.
Related Topics and Keywords
Subscribe to our FREE newsletter